Home Stocks CSTL Castle Biosciences Inc (NASDAQ: CSTL) Healthcare · Diagnostics & Research
$33.38 +0.40 (+1.21%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. CSTL rose 1.21% in the Nov 18 session to $33.38. The borrow fee is 0.28%. Six active firms cover the stock as of Nov 19, 2026; six active firms with targets average $44.33 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Broadly in line with peers P/S 2.8× vs peer median 4.5×
Momentum Neutral RSI (14) 45.1 (overbought above 70, oversold below 30)
Short interest 7.7% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $32.88 Nov 18, 2026 session
Previous close $32.98 Nov 17, 2026 close
Day range $32.34 – $34.09 Nov 18, 2026 session
52-week range —
Volume 380.85K Nov 18, 2026 session
Average volume (30 calendar days) —
Market cap —
P/E (TTM) —
Forward P/E —
EPS (TTM) —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history CSTL · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
How CSTL compares with its industry Against 44 other US-listed Diagnostics & Research stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsFive-year annualized sales growth was 40.6%, higher than 97% of 31 peers.Peer median 7.5% · As of Nov 17, 2026 Trailing-year gross margin was 77.1%, higher than 95% of 41 peers.Peer median 55.0% · As of Nov 17, 2026 Current ratio was 5.28, higher than 85% of 41 peers.Peer median 2.31 · As of Nov 17, 2026 Valuation Broadly in line with peers
Metric CSTL Peer median
Profitability Profitability metrics are mixed versus peers.
Metric CSTL Peer median
Growth Growth metrics are higher than most peers.
Metric CSTL Peer median
Balance sheet Balance sheet metrics are higher than most peers.
Metric CSTL Peer median
Momentum Returns are mixed versus peers.
Metric CSTL Peer median
How to read this The dot marks where CSTL ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 17, 2026
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
6 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 6 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $40.00
Average $44.33
High $52.00
As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast → Earnings history — · Earnings history not available
Smart-money activity In the last 60 days: 29 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Nov 16, 2026 Insider sell MAETZOLD DEREK J Sell $46.0K Form 4 Nov 16, 2026 Insider sell MAETZOLD DEREK J Sell $54.1K Form 4 Nov 16, 2026 Insider sell MAETZOLD DEREK J Sell $128.5K Form 4 Nov 11, 2026 Insider sell Juvenal Tobin W Sell $112.0K Form 4 Nov 11, 2026 Insider sell Juvenal Tobin W Sell $99.1K Form 4 Nov 9, 2026 Insider sell Juvenal Tobin W Sell $107.4K Form 4 Nov 2, 2026 Insider sell MAETZOLD DEREK J Sell $12.0K Form 4 Nov 2, 2026 Insider sell MAETZOLD DEREK J Sell $14.1K Form 4 Nov 2, 2026 Insider sell MAETZOLD DEREK J Sell $37.7K Form 4 Nov 2, 2026 Insider sell MAETZOLD DEREK J Sell $86.2K Form 4 All smart-money activity →
News and press releases News and press releases are not available.
All CSTL news → Company profile Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to
CEO Mr. Derek J. Maetzold
Headquarters Friendswood, TX, United States
Employees 1,048
IPO date Jul 25, 2019
Sector Healthcare
Industry Diagnostics & Research Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
6 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 6 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $40.00
Average $44.33
High $52.00
As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast → Earnings history — · Earnings history not available
Company profile Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to
CEO Mr. Derek J. Maetzold
Headquarters Friendswood, TX, United States
Employees 1,048
IPO date Jul 25, 2019
Sector Healthcare
Industry Diagnostics & Research